Results 31 to 40 of about 280,420 (306)

Neutrophil-like cell membrane-coated siRNA of lncRNA AABR07017145.1 therapy for cardiac hypertrophy via inhibiting ferroptosis of CMECs

Molecular Therapy: Nucleic Acids, 2022
Cardiac microvascular dysfunction is associated with cardiac hypertrophy and can eventually lead to heart failure. Dysregulation of long non-coding RNAs (lncRNAs) has recently been recognized as one of the key mechanisms involved in cardiac hypertrophy ...
Pilong Shi, Minghui Li, Chao Song, Hanping Qi, Lina Ba, Yonggang Cao, Meitian Zhang, Yawen Xie, Jing Ren, Jiabi Wu, Ping Ren, Hongli Sun   +11 more
doaj   +1 more source

Bellidifolin ameliorates isoprenaline-induced cardiac hypertrophy by the Nox4/ROS signalling pathway through inhibiting BRD4

Cell Death Discovery, 2023
To date, there is no effective therapy for pathological cardiac hypertrophy, which can ultimately lead to heart failure. Bellidifolin (BEL) is an active xanthone component of Gentianella acuta (G. acuta) with a protective function for the heart. However,
Dingyan Zhou, Weizhe Liu, Juanjuan Zhang, Yucui Dong, Jiangli Wu, Yu Zhang, Cheng Dai, Tingting Zhang, Gaoshan Yang, Yue Zhang, Aiying Li   +10 more
doaj   +1 more source

Ventricular androgenic-anabolic steroid-related remodeling: an immunohistochemical study [PDF]

, 2017
Background: Several fatal cases of bodybuilders, following a myocardial infarction after long exposure to androgenicanabolic steroids (AAS), are reported. In recent years, evidence has emerged of cases of heart failure related to AAS consumption, with no
Cecchi, Rossana, Ciallella, Costantino, DI LUCA, Natale Mario, Kimura, Akihiko, Kondo, Toshikazu, Muciaccia, Barbara, Nosaka, Mizuho, Sestili, Cristina   +7 more
core   +1 more source

A Disintegrin and Metalloprotease‐22 Attenuates Hypertrophic Remodeling in Mice Through Inhibition of the Protein Kinase B Signaling Pathway

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, 2018
Background Severe cardiac hypertrophy can lead to cardiac remodeling and even heart failure in the end, which is a leading cause of cardiovascular disease–related mortality worldwide.
Lingyun Ren, Chuangyan Wu, Kai Yang, Shanshan Chen, Ping Ye, Jie Wu, Anchen Zhang, Xiaofan Huang, Ke Wang, Peng Deng, Xiangchao Ding, Manhua Chen, Jiahong Xia   +12 more
doaj   +1 more source

Micro-RNA family that modulates fibrosis and uses thereof [PDF]

, 2017
The present invention relates to the identification of a microRNA family, designated miR-29a-c, that is a key regulator of fibrosis in cardiac tissue. The inventors show that members of the miR-29 family are down-regulated in the heart tissue in response
Olson, Eric N., van Rooij, Eva
core   +1 more source

Time spent with cats is never wasted: Lessons learned from feline acromegalic cardiomyopathy, a naturally occurring animal model of the human disease [PDF]

, 2018
BackgroundIn humans, acromegaly due to a pituitary somatotrophic adenoma is a recognized cause of increased left ventricular (LV) mass. Acromegalic cardiomyopathy is incompletely understood, and represents a major cause of morbidity and mortality.
A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Colao, A Mestron, A Piovesan, AC Dirtu, AM Pereira, B Posch, BJ Maron, BPP Meij, BR Bond, C Paige, C-Y Liu, CJL Little, CR Lamb, David B. Church, David J. Connolly, DJ Connolly, F Fracassi, G Jacobs, G Lombardi, G Lombardi, J Dal, J Gilbert, JA Myers, JK Sangster, JM Fletcher, JR Payne, JT Lie, Kieran Borgeat, LJ Wilkie, Lois Wilkie, M Galderisi, M Lesser, M Maxie Grant, M Nishiki, M Rosca, M-LL Jaffrain-Rea, MD Kittleson, ME Peterson, ME Peterson, NJ Pereira, Norelene Harrington, NS Moise, NS Moise, O Kershaw, OM Dekkers, P Menaut, PR Fox, PR Fox, PR Fox, PR Fox, PR Fox, R Baldelli, R Gostelow, R Pivonello, RC Weichselbaum, S Brown, S Fazio, S Fazio, S Fazio, S Fieffe, S Murarka, S Niessen, SJM Niessen, SJM Niessen, SJM Niessen, SK Liu, SK Liu, Stijn J. M. Niessen, SV Keyte, T Wagner, T. Rosol, Vincenzo Lionetti, Virginia Luis Fuentes, WL McGuffin   +80 more
core   +2 more sources

Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors

Frontiers in Cardiovascular Medicine, 2022
Cardiac hypertrophy is a key process in cardiac remodeling development, leading to ventricle enlargement and heart failure. Recently, studies show the complicated relation between cardiac hypertrophy and epigenetic modification.
Yu Han, Yu Han, Jiali Nie, Jiali Nie, Dao Wen Wang, Dao Wen Wang, Li Ni, Li Ni   +7 more
doaj   +1 more source

Eccentric and concentric cardiac hypertrophy induced by exercise training: microRNAs and molecular determinants

Brazilian Journal of Medical and Biological Research, 2011
Among the molecular, biochemical and cellular processes that orchestrate the development of the different phenotypes of cardiac hypertrophy in response to physiological stimuli or pathological insults, the specific contribution of exercise training has ...
T. Fernandes, U.P.R. Soci, E.M. Oliveira
doaj   +3 more sources

Protein phosphatases in pathological cardiac hypertrophy [PDF]

Yixue xinzhi zazhi
Pathological cardiac hypertrophy is a pathological change of various cardiovascular disease, caused by persistent mechanical and chemical stimulation, which ultimately leads to heart failure and arrhythmia.
ZHANG Xutao, XIA Hao
doaj   +1 more source

Pre-Participation Cardiac Screening: consideration for Young Athletes [PDF]

, 2010
This article is the first of two focusing on the utility and evidence base for pre-participation cardiac screening in competitive athletic populations.
Ingle, L
core   +1 more source